Takeda Grabs Shire At Last After Long Pursuit
Takeda and Shire see their £46bn combination bringing commercial and pipeline strengths across multiple therapeutic areas, along with opportunities for cost synergies and strengthening in key geographic markets.
You may also be interested in...
Sun Outstrips Viatris’ Pentasa Action Date With First ANDA Approval
Sun Pharma has scooped a first ANDA approval for a rival to Takeda’s mesalamine-containing brand Pentasa, with Viatris making clear recently that it was eyeing a first-time generic launch for the gastrointestinal drug.
Takeda Teams With Evozyne On Protein Design For Gene Therapy
Deal Snapshot: Building on a 2021 tie-up between Takeda and the Paragon start-up, Evozyne will seek novel protein sequences for inclusion in gene therapies for rare disease indications.
Asia Deal Watch: SV Investment And Orange Grove Will Team Up On New Company Effort
Takeda spins out Oak Hill Bio, Lupin and Axantia will co-develop filgrastim biosimilar and Xbiome licenses skin ulcer candidate from Aurealis.